UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2008

Rockwell Medical Technologies, Inc.

(Exact name of registrant as specified in its charter)

Michigan	000-23661	38-3317208
(State or other jurisdiction of incorporation)	(Commission file number)	(I.R.S. Employer Identification No.)

30142 Wixom Road,Wixom, Michigan	48393
(Address of principal executive offices)	(Zip Code)

(248) 960-9009

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2008, the Company issued the press release attached hereto Exhibit 99.1, announcing its financial results for the quarter ended September 30, 2008.

Item 9.01. Financial Statements and Exhibits.

(c)	Exhibits.

	The following exhibits are furnished with this Form 8-K:

	Exhibit	Description

	99.1	Press Release dated November 13, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Rockwell Medical Technologies, Inc.

Date: November 13, 2008	By:	/s/ THOMAS E. KLEMA
		Thomas E. Klema Its: Chief Financial Officer

EXHIBIT INDEX

Exhibit		Description

99.1		Press Release dated November 13, 2008.

* Quarterly sales of $13.5 million increased 22.2% or $2.5 million compared to 2007. * Domestic sales were up 12.3% compared to the third quarter of 2007. * Sequential domestic revenue increased 11.1% in the third quarter over the second quarter. * Gross profit decreased due to higher than expected transportation costs. * SG&A expense in 2008 included a litigation settlement charge of $750,000 and non-cash charges for stock options and warrants of $0.3 million. * SFP related R&D spending of $1.0 million or 7.3% of sales in 2008. * Loss of ($2.5 million) compared to a loss of ($.4 million) in the third quarter 2007. * Cash position at September 30, 2008 was $7.5 million.

* Sales increased 22.6% or $7.0 million to $38.1 million in the first nine months of 2008 vs. 2007. * Domestic sales increased 16.7% while international sales were up 147% compared to the first nine months of 2007. * Gross profit increased by $573,000 or 26.6% compared to the first nine months of 2007. * SG&A expense in 2008 included a litigation settlement charge of $750,000 and non-cash charges for stock options and warrants of $1.1 million. * R&D expense was $2.6 million for the first nine months of 2008 compared to $2.3 million in the first nine months of 2007. * Loss of ($4.8 million) compared to a loss of ($2.6 million) in the first nine months of 2007.

* Data Safety Monitoring Board (DSMB), which oversees the SFP Phase IIb dose-range study, met in October and cited no safety issues; recommended continuation of study. * More than 1,500 doses of SFP administered amongst Phase IIa, Phase IIb and National Institutes of Health (NIH) study with no serious adverse events reported. * Implemented changes to SFP Phase IIb study protocol to accelerate enrollment. * Increased number of SFP clinical trial sites to 25+. * NIH study continuing to enroll patients. * Added significant expertise to the Company's Scientific Advisory Board with the appointment of additional iron experts in the renal field. * Progressed in recruitment of a Chief Medical Officer.

ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY CONSOLIDATED INCOME STATEMENTS For the three and nine months ended Sept. 30, 2008 and Sept. 30, 2007 (Unaudited) Three Months Three Months Nine Months Nine Months Ended Ended Ended Ended Sept. 30, Sept. 30, Sept. 30, Sept. 30, 2008 2007 2008 2007 ------------ ------------ ------------ ------------ Sales $ 13,533,986 $ 11,073,774 $ 38,128,359 $ 31,096,399 Cost of Sales 12,755,377 9,953,863 35,400,671 28,942,171 ------------ ------------ ------------ ------------ Gross Profit 778,609 1,119,911 2,727,688 2,154,228 Selling, General and Administra- tive 2,314,188 765,457 5,183,675 2,288,903 Research and Product Development 993,262 735,393 2,557,718 2,319,452 ------------ ------------ ------------ ------------ Operating (Loss) (2,528,841) (380,939) (5,013,705) (2,454,127) Interest Expense (Income), net (17,795) 51,973 (182,482) 101,924 ------------ ------------ ------------ ------------ Net (Loss) $ (2,511,046) $ (432,912) $ (4,831,223) $ (2,556,051) ============ ============ ============ ============ Basic Earnings (Loss) per Share ($.18) ($.04) ($.35) ($.22) Diluted Earnings (Loss) per Share ($.18) ($.04) ($.35) ($.22) ROCKWELL MEDICAL TECHNOLOGIES, INC. AND SUBSIDIARY CONSOLIDATED BALANCE SHEETS As of September 30, 2008 and December 31, 2007 September 30, December 31, ASSETS 2008 2007 ------------ ------------ (Unaudited) Cash and Cash Equivalents $ 7,481,792 $ 11,097,192 Accounts Receivable, net of a reserve of $96,000 in 2008 and $69,000 in 2007 5,356,536 4,687,229 Inventory 3,166,566 2,559,051 Other Current Assets 535,437 302,573 ------------ ------------ Total Current Assets 16,540,331 18,645,945 Property and Equipment, net 3,332,569 2,840,331 Intangible Assets 248,338 270,446 Goodwill 920,745 920,745 Other Non-current Assets 116,850 125,667 ------------ ------------ Total Assets $ 21,158,833 $ 22,803,134 ============ ============ LIABILITIES AND SHAREHOLDERS' EQUITY Notes Payable & Capitalized Lease Obligations $ 187,682 $ 194,239 Accounts Payable 3,977,321 2,982,899 Accrued Liabilities 2,252,257 1,122,737 Customer Deposits 331,043 337,396 ------------ ------------ Total Current Liabilities 6,748,303 4,637,271 Long Term Notes Payable & Capitalized Lease Obligations 58,190 204,837 Shareholders' Equity: Common Shares, no par value, 13,834,953 and 13,815,186 shares issued and outstanding 34,224,870 33,415,106 Common Share Purchase Warrants, 1,414,169 and 1,204,169 warrants issued and outstanding 3,413,443 3,038,411 Accumulated Deficit (23,323,714) (18,492,491) ------------ ------------ Total Shareholders' Equity 14,352,340 17,961,026 ------------ ------------ Total Liabilities And Shareholders' Equity $ 21,158,833 $ 22,803,134 ============ ============

Rockwell Medical Technologies, Inc. Reports Third Quarter Results; Sales Gain of 22.2 Percent